Journal Mobile Options
Table of Contents
Vol. 51, No. 2, 2005
Issue release date: March–April 2005
Gerontology 2005;51:142–144

Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal Fluid

Bleich S. · Otto M. · Zerr I. · Kropp S. · Kretzschmar H.A. · Wiltfang J.
aDepartment of Psychiatry and Psychotherapy, Friedrich-Alexander-University, Erlangen-Nuremberg, bDepartment of Neurology, Georg-August-University Göttingen, cDepartment of Psychiatry and Psychotherapy, Medical School University, Hannover, and dInstitute of Neuropathology, Ludwig-Maximilians-University, Munich, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: There is evidence that homocysteine contributes to various neurodegenerative disorders. Objective: To assess the values of homocysteine in patients with Creutzfeldt-Jakob disease (CJD) in both cerebrospinal fluid (CSF) and plasma. Methods: Study design: Case control study. Total homocysteine was quantified in CSF and plasma samples of CJD patients (n = 13) and healthy controls (n = 13). Results: Mean values in healthy controls: 0.15 µmol/l ± 0.07 (CSF) and 9.10 µmol/l ± 2.99 (plasma); mean values in CJD patients: 0.13 µmol/l ± 0.03 (CSF) and 9.22 µmol/l ± 1.81 (plasma). No significant differences between CJD patients and controls were observed (Mann-Whitney U, p > 0.05). Conclusions: The results indicate that the CSF and plasma of CJD patients showed no higher endogenous levels of homocysteine as compared to normal healthy controls. These findings provide no evidence for an additional role of homocysteine in the pathogenetic mechanisms underlying CJD neurodegeneration.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bleich S, Kropp S, Degner D, Zerr I, Pilz J, Gleiter CH, Otto M, Ruther E, Kretzschmar HA, Wiltfang J, Kornhuber J, Poser S: Creutzfeldt-Jakob disease and oxidative stress. Acta Neurol Scand 2000;101:332–334.
  2. Bleich S, Jünemann A, von Ahsen N, Lausen B, Ritter K, Beck G, Naumann GO, Kornhuber J: Homocysteine and risk of open-angle glaucoma. J Neural Transm 2002;109:1499–1504.
  3. Bleich S, Bandelow B, Javaheripour K, Müller A, Degner D, Wilhelm J, Havemann-Reinecke U, Sperling W, Rüther E, Kornhuber J: Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett 2003;335:179–182.
  4. Bottiglieri T: Folate, vitamin B12 and neuropsychiatric disorders. Nutr Rev 1996;54:382–390.
  5. Halliwell B, Gutteridge JMC: Oxygen toxicity, oxygen radicals, transition metals and disease (review article). Biochem J 1984:219:1–14.
  6. Lipton SA, Kim WK, Choi YB, Kumar S, D’Emilia DM, Rayudu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923–5928.
  7. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S: Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58:192–197.
  8. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002;346:476–483.
  9. Ubbink JB, Becker PJ, Vermaak WJ, Delport R: Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995;41:1033–1037.
  10. Zerr I, Bodemer M, Weber T: The 14-3-3 brain protein and transmissible spongiform encephalopathy. N Engl J Med 1997;336:874.
  11. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, Bernheimer H, Cardone F, Delasnerie-Laupretre N, Cuadrado Corrales N, Ladogana A, Bodemer M, Fletcher A, Awan T, Ruiz Bremon A, Budka H, Laplanche JL, Will RG, Poser S: Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811–815.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00